Insulet (Nasdaq: PODD) announced that it began a limited market release of the Omnipod 5 with the Dexcom G7. This marks the latest integration of Dexcom’s next-generation CGM into automated insulin delivery technology. Omnipod 5, Insulet’s newest patch pump offering, previously worked with the G6 in the U.S. It also recently integrated the system with […]
Wall Street Beat
Tandem stock dips after hours on Q4 misses, 10% growth expected in 2024
Tandem Diabetes Care (Nasdaq:TNDM) shares took a hit after hours on fourth-quarter results that came up short of the consensus forecast. Shares of TNDM fell 8% at $20.74 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up 0.2%. […]
Embecta beats The Street in Q1, raises guidance as insulin pump development moves along
Embecta (Nasdaq:EMBC) shares took a hit this morning despite Street-beating first-quarter results and increased 2024 guidance. Shares of EMBC fell 7.8% at $16.37 apiece as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — opened today relatively even. The Parsippany, New Jersey-based BD Diabetes […]
Dexcom says revenues could grow 20% in 2024
Dexcom (Nasdaq:DXCM) shares dipped after hours on fourth-quarter results that came in ahead of the consensus forecast. Shares of DXCM fell 1.6% at $125 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 0.2%. The San Diego-based continuous […]
Senseonics posts mixed Q3, iCGM designation expected next year
Senseonics (NYSE:SENS) shares remained mostly unchanged today on third-quarter results that came in mixed compared to the consensus forecast. Shares of SENS dipped 0.3% at 51¢ apiece before the market opened today. The Germantown, Maryland-based implantable continuous glucose monitor (CGM) maker posted losses of $24.1 million. That equals 4¢ per share on sales of $6.1 […]
Insulet stock soars on Q3 results, Dexcom G7 integration planned for early 2024
Insulet (Nasdaq:PODD) shares got a boost from third-quarter results that came in ahead of the consensus forecast. Shares of PODD were up more than 16% at $162.94 near the end of trading today — a day after the company released results after market close. MassDevice’s MedTech 100 Index — which includes stocks of the world’s […]
Tandem stock sinks after hours on Q3 misses, lowered guidance
Tandem Diabetes Care (Nasdaq:TNDM) shares took a massive hit after hours today on third-quarter results that missed the consensus forecast. Shares of TNDM fell nearly 20% at $14.27 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 1.1%. The […]
Dexcom stock rises after hours on raised 2023 guidance, $500M share repurchase program
Dexcom (Nasdaq:DXCM) shares got a massive boost on third-quarter results that came in well ahead of the consensus forecast. The San Diego-based continuous glucose monitor (CGM) maker also announced a $500 million share repurchase program in conjunction with its third-quarter results. The repurchase program follows a $1 billion senior convertible note offering this year, plus […]
Bausch+Lomb launches $1.4B offering to finance XIIDRA eye drop buy
Bausch + Lomb (NYSE:BLCO) announced today that it launched an offering worth $1.4 billion in new senior secured notes. The company intends to offer the notes, due 2028, and to enter into an incremental term loan facility. Both moves aim to support the financing of the company’s pending acquisition of XIIDRA. Bausch + Lomb expects […]
Analysts: GLP-1 drugs should have minor impact on insulin pump market — but will boost CGMs
Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry. The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to […]
